-+ 0.00%
-+ 0.00%
-+ 0.00%

AN2 THERAPEUTICS - PHASE 1 STUDY SHOWS FAVORABLE SAFETY AND NO DOSE-LIMITING TOXICITIES FOR AN2-502998

Reuters·06/04/2026 11:00:02

Please log in to view news